You are here: Industry Insights > multiple sclerosis

News List

Updated restrictions announced for multiple sclerosis treatment europeanpharmaceuticalreview
March 11, 2020
A revised indication, additional contraindications and strengthened monitoring requirements has been recommended for Lemtrada (alemtuzumab) following a review.
The gut may be involved in the development of multiple sclerosis worldpharmanews
December 09, 2019
It is incompletely understood which factors in patients with multiple sclerosis (MS) act as a trigger for the immune system to attack the brain and spinal cord.
FDA approves first generics of Gilenya expresspharma
December 09, 2019
The US Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.
FDA approves generics of Novartis multiple sclerosis drug Gilenya pharmaceutical-technology
December 09, 2019
The US Food and Drug Administration (FDA) has approved the first generic versions of Novartis multiple sclerosis drug Gilenya (fingolimod).
Space study seeks treatments for Parkinson’s, multiple sclerosis expresspharma
August 05, 2019
Scientists are conducting a first-of-its-kind study on the International Space Station (ISS) to find the causes and treatment of major neurodegenerative diseases such as Parkinson’s and multiple sclerosis.
A Blockbuster to Arrive in the Multiple Sclerosis Area of China! PharmaSources/Caicai
July 24, 2019
Novartis’ Fingolimod with Annual Sales Exceeding USD3 Billion to be Marketed Soon in China
Novartis' key multiple sclerosis product Gilenya gets approval in China biospectrumasia
July 20, 2019
Chinese National Medical Products Administration (NMPA) approved Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older
Significant Number of Referred Patients Misdiagnosed With MS drugs
April 28, 2019
Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events than interferon beta-1a, according to a study published in the Sept.
Novartis' MS drug gets FDA approval pharmatimes
March 28, 2019
The US Food and Drug Administration (FDA) has approved Novartis’ Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS).
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting firstwordpharma
February 23, 2019
These data support the ongoing, fully enrolled, international Phase 3 program evaluating ublituximab (TG-1101) for the treatment of relapsing form of Multiple Sclerosis (RMS).

Previous page 1 2 3 4 5 6 Next page